Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;62(1):72-76.
doi: 10.1111/apt.70139. Epub 2025 Apr 7.

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study

Saqr Alsakarneh  1 , Omar Al Ta'ani  2 , Razan Aburumman  3 , Inas Mikhail  4 , Jana G Hashash  4 , Francis A Farraye  4
Affiliations

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study

Saqr Alsakarneh et al. Aliment Pharmacol Ther. 2025 Jul.

Abstract

IL-17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL-17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL-17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85-3.39). IL-17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.

Keywords: IL‐17 inhibitors; Secukinumab; inflammatory bowel disease.

PubMed Disclaimer

References

    1. J. R. Maxwell, Y. Zhang, W. A. Brown, et al., “Differential Roles for Interleukin‐23 and Interleukin‐17 in Intestinal Immunoregulation,” Immunity 43, no. 4 (2015): 739–750, https://doi.org/10.1016/j.immuni.2015.08.019.
    1. A. Silfvast‐Kaiser, S. Y. Paek, and A. Menter, “Anti‐IL17 Therapies for Psoriasis,” Expert Opinion on Biological Therapy 19, no. 1 (2019): 45–54.
    1. M. Fauny, D. Moulin, F. D'Amico, et al., “Paradoxical Gastrointestinal Effects of Interleukin‐17 Blockers,” Annals of the Rheumatic Diseases 79, no. 9 (2020): 1132–1138.
    1. TriNetX, accessed January 22, 2025, https://trinetx.com/.
    1. S. Danese, M. F. Neurath, A. Kopoń, et al., “Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis,” Clinical Gastroenterology and Hepatology 18, no. 11 (2020): 2526–2534.e9.

MeSH terms

LinkOut - more resources